Faruqi & Faruqi Reminds Elevance Health Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 11, 2025 - ELV

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation - The law firm is looking into claims against Elevance Health, reminding investors of the July 11, 2025 deadline to seek lead plaintiff status in a federal securities class action [2]. - The complaint alleges that Elevance and its executives made false or misleading statements regarding the monitoring of cost trends and the adequacy of premium rates for Medicaid programs [4]. Group 2: Financial Disclosures - On July 17, 2024, Elevance disclosed an expectation of increased Medicaid utilization, leading to a stock price decline of $32.21 per share, or 5.8% [5]. - The company further revealed on October 17, 2024, that it missed consensus earnings per share expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [6]. - Following these disclosures, Elevance's stock price fell by another $52.61 per share, or 10.6% [7]. Group 3: Class Action Participation - The lead plaintiff in the class action is the investor with the largest financial interest who directs the litigation on behalf of the class, with options for other members to participate or remain absent [8]. - The firm encourages anyone with information regarding Elevance's conduct to contact them, including whistleblowers and former employees [9].